PROTEIN C VARIANTS WITH ALTERED PROPERTIES

摘要

The invention relates to the use of a human protein C variant comprising at least one amino acid modification in position 306-314, e.g. substitution of a charged residue with an uncharged residue, for the manufacture of a medicament for the treatment of a hypercoagulable state or acquired protein C deficiency, e.g. for the treatment of sepsis. The variants have a reduced anticoagulant activity compared to non-modified human activated protein C.